CI
IBRX icon

Cordant Inc’s ImmunityBio IBRX Stock Holding History

Cordant Inc’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13
Closed – – 615
2022
Q1 		$0 Buy
+13
New +$80 ﹤0.01% 1295

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cordant Inc's IBRX Position: Q2 2022 in Review

Cordant Inc sold out of ImmunityBio (IBRX) in Q2 2022, closing a stake of 13 shares.

Cordant Inc first reported a position in IBRX in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 131 funds tracked by Wall St. Rank hold IBRX as of Q2 2022.

  • Cordant Inc reported no remaining ImmunityBio position as of Q2 2022 after selling out during the quarter.
  • Cordant Inc sold 13 ImmunityBio shares in Q2 2022.
  • Cordant Inc first reported a position in ImmunityBio in Q1 2022 and held it in 1 quarter.
  • Cordant Inc's ImmunityBio position peaked at $0 in Q1 2022.
  • 131 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.